PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
13.12%
Revenue growth above 1.5x MRVL's 4.29%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
16.17%
Gross profit growth above 1.5x MRVL's 3.82%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
10.22%
EBIT growth 1.25-1.5x MRVL's 8.09%. Bruce Berkowitz would verify if strategic initiatives are driving this edge.
12.17%
Operating income growth at 75-90% of MRVL's 15.99%. Bill Ackman would demand a plan to enhance operating leverage.
13.43%
Positive net income growth while MRVL is negative. John Neff might see a big relative performance advantage.
8.33%
Positive EPS growth while MRVL is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
8.70%
Positive diluted EPS growth while MRVL is negative. John Neff might view this as a strong relative advantage in controlling dilution.
2.53%
Slight or no buybacks while MRVL is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
1.38%
Diluted share count expanding well above MRVL's 1.17%. Michael Burry would fear significant dilution to existing owners' stakes.
0.49%
Maintaining or increasing dividends while MRVL cut them. John Neff might see a strong edge in shareholder returns.
83.58%
Positive OCF growth while MRVL is negative. John Neff would see this as a clear operational advantage vs. the competitor.
152.78%
Positive FCF growth while MRVL is negative. John Neff would see a strong competitive edge in net cash generation.
12.26%
10Y revenue/share CAGR under 50% of MRVL's 56.20%. Michael Burry would suspect a lasting competitive disadvantage.
-16.56%
Negative 5Y CAGR while MRVL stands at 109.65%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
101.94%
3Y revenue/share CAGR above 1.5x MRVL's 25.49%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
153.21%
10Y OCF/share CAGR at 50-75% of MRVL's 237.57%. Martin Whitman might fear a structural deficiency in operational efficiency.
94.23%
5Y OCF/share CAGR above 1.5x MRVL's 45.44%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
34.58%
3Y OCF/share CAGR at 50-75% of MRVL's 63.72%. Martin Whitman would suspect weaker recent execution or product competitiveness.
882.41%
Net income/share CAGR 1.25-1.5x MRVL's 653.69%. Bruce Berkowitz might see more effective use of capital or consistently better margins over time.
108.68%
Below 50% of MRVL's 220.76%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
1537.14%
3Y net income/share CAGR above 1.5x MRVL's 202.86%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
188.07%
10Y equity/share CAGR above 1.5x MRVL's 54.87%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
162.02%
5Y equity/share CAGR above 1.5x MRVL's 19.67%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
99.34%
Positive short-term equity growth while MRVL is negative. John Neff sees a strong advantage in near-term net worth buildup.
10.49%
10Y dividend/share CAGR above 1.5x MRVL's 0.04%. David Dodd checks if the firm's robust cash flows justify outpacing the competitor's increases.
27.18%
Stable or rising mid-term dividends while MRVL is cutting. John Neff sees an edge in consistent payouts vs. the competitor.
-6.24%
Both firms reduced dividends recently. Martin Whitman suspects broader macro or industry issues forcing cost and payout cuts.
-5.96%
Firm’s AR is declining while MRVL shows 11.24%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
18.73%
Inventory growth well above MRVL's 4.05%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
13.87%
Positive asset growth while MRVL is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
13.93%
Positive BV/share change while MRVL is negative. John Neff sees a clear edge over a competitor losing equity.
-0.91%
We’re deleveraging while MRVL stands at 3.89%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-3.71%
Our R&D shrinks while MRVL invests at 1.74%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
28.49%
We expand SG&A while MRVL cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.